Brolucizumab
Beovu (brolucizumab) is an antibody pharmaceutical. Brolucizumab was first approved as Beovu on 2019-10-07. It is used to treat wet macular degeneration in the USA. It has been approved in Europe to treat wet macular degeneration. The pharmaceutical is active against vascular endothelial growth factor A.
| Trade Name | Beovu |
|---|---|
| Common Name | Brolucizumab |
| Indication | wet macular degeneration |
| Drug Class | Monoclonal antibodies: humanized, cardiovascular indications |
